Chugai Pharmaceutical Co. Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL… Read more
Chugai Pharmaceutical Co. Ltd (CHGCF) - Net Assets
Latest net assets as of December 2025: $2.03 Trillion USD
Based on the latest financial reports, Chugai Pharmaceutical Co. Ltd (CHGCF) has net assets worth $2.03 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.47 Trillion) and total liabilities ($443.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.03 Trillion |
| % of Total Assets | 82.06% |
| Annual Growth Rate | 9.11% |
| 5-Year Change | 70.66% |
| 10-Year Change | 213.61% |
| Growth Volatility | 6.13 |
Chugai Pharmaceutical Co. Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Chugai Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chugai Pharmaceutical Co. Ltd (2003–2025)
The table below shows the annual net assets of Chugai Pharmaceutical Co. Ltd from 2003 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.03 Trillion | +6.63% |
| 2024-12-31 | $1.90 Trillion | +16.97% |
| 2023-12-31 | $1.63 Trillion | +14.12% |
| 2022-12-31 | $1.42 Trillion | +19.90% |
| 2021-12-31 | $1.19 Trillion | +21.23% |
| 2020-12-31 | $980.00 Billion | +14.76% |
| 2019-12-31 | $853.99 Billion | +12.88% |
| 2018-12-31 | $756.53 Billion | +9.18% |
| 2017-12-31 | $692.90 Billion | +7.18% |
| 2016-12-31 | $646.50 Billion | +3.07% |
| 2015-12-31 | $627.27 Billion | +4.94% |
| 2014-12-31 | $597.76 Billion | +4.28% |
| 2013-12-31 | $573.20 Billion | +16.96% |
| 2012-12-31 | $490.07 Billion | +6.75% |
| 2011-12-31 | $459.07 Billion | +2.15% |
| 2010-12-31 | $449.39 Billion | +3.38% |
| 2009-12-31 | $434.69 Billion | +9.47% |
| 2008-12-31 | $397.07 Billion | +2.92% |
| 2007-12-31 | $385.80 Billion | -1.48% |
| 2006-12-31 | $391.60 Billion | +5.84% |
| 2005-12-31 | $370.00 Billion | +14.80% |
| 2004-12-31 | $322.31 Billion | +8.30% |
| 2003-12-31 | $297.62 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chugai Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1213.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.89 Trillion | 93.30% |
| Common Stock | $73.27 Billion | 3.61% |
| Other Comprehensive Income | $-8.03 Billion | -0.40% |
| Other Components | $70.58 Billion | 3.48% |
| Total Equity | $2.03 Trillion | 100.00% |
Chugai Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Chugai Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HUATEI SECS.CO GDR S/10
F:206G
|
$28.31 Billion |
|
FirstEnergy Corporation
NYSE:FE
|
$28.32 Billion |
|
Tata Consultancy Services Limited
NSE:TCS
|
$28.40 Billion |
|
Halliburton Company
NYSE:HAL
|
$28.43 Billion |
|
Workday Inc
NASDAQ:WDAY
|
$28.24 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
$28.19 Billion |
|
Sampo OYJ
PINK:SAXPY
|
$28.18 Billion |
|
Verisk Analytics Inc
NASDAQ:VRSK
|
$28.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chugai Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,901,499,000,000 to 2,027,499,678,000, a change of 126,000,678,000 (6.6%).
- Net income of 434,390,724,000 contributed positively to equity growth.
- Dividend payments of 299,680,277,000 reduced retained earnings.
- Share repurchases of 6,005,000 reduced equity.
- Other comprehensive income decreased equity by 19,500,004,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $434.39 Billion | +21.42% |
| Dividends Paid | $299.68 Billion | -14.78% |
| Share Repurchases | $6.00 Million | -0.0% |
| Other Comprehensive Income | $-19.50 Billion | -0.96% |
| Other Changes | $10.80 Billion | +0.53% |
| Total Change | $- | 6.63% |
Book Value vs Market Value Analysis
This analysis compares Chugai Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.25x to 0.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $179.62 | $44.23 | x |
| 2004-12-31 | $192.70 | $44.23 | x |
| 2005-12-31 | $219.76 | $44.23 | x |
| 2006-12-31 | $234.79 | $44.23 | x |
| 2007-12-31 | $233.50 | $44.23 | x |
| 2008-12-31 | $241.83 | $44.23 | x |
| 2009-12-31 | $264.93 | $44.23 | x |
| 2010-12-31 | $274.37 | $44.23 | x |
| 2011-12-31 | $280.39 | $44.23 | x |
| 2012-12-31 | $299.29 | $44.23 | x |
| 2013-12-31 | $349.54 | $44.23 | x |
| 2014-12-31 | $363.95 | $44.23 | x |
| 2015-12-31 | $381.53 | $44.23 | x |
| 2016-12-31 | $393.36 | $44.23 | x |
| 2017-12-31 | $421.32 | $44.23 | x |
| 2018-12-31 | $459.63 | $44.23 | x |
| 2019-12-31 | $519.29 | $44.23 | x |
| 2020-12-31 | $595.72 | $44.23 | x |
| 2021-12-31 | $722.10 | $44.23 | x |
| 2022-12-31 | $865.71 | $44.23 | x |
| 2023-12-31 | $987.89 | $44.23 | x |
| 2024-12-31 | $1155.48 | $44.23 | x |
| 2025-12-31 | $1231.98 | $44.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chugai Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.50%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.22x
- Recent ROE (21.42%) is above the historical average (13.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 9.59% | 12.22% | 0.57x | 1.37x | $-1.23 Billion |
| 2004 | 10.63% | 11.58% | 0.72x | 1.28x | $2.03 Billion |
| 2005 | 14.56% | 16.39% | 0.72x | 1.24x | $16.80 Billion |
| 2006 | 9.86% | 11.78% | 0.71x | 1.19x | $-542.80 Million |
| 2007 | 10.44% | 11.62% | 0.75x | 1.20x | $1.70 Billion |
| 2008 | 9.93% | 12.01% | 0.68x | 1.21x | $-276.50 Million |
| 2009 | 13.08% | 13.20% | 0.79x | 1.25x | $13.34 Billion |
| 2010 | 9.25% | 10.92% | 0.75x | 1.13x | $-3.37 Billion |
| 2011 | 7.70% | 9.43% | 0.70x | 1.17x | $-10.55 Billion |
| 2012 | 9.86% | 12.32% | 0.67x | 1.20x | $-682.00 Million |
| 2013 | 8.90% | 12.01% | 0.61x | 1.22x | $-6.27 Billion |
| 2014 | 8.55% | 11.06% | 0.62x | 1.24x | $-8.63 Billion |
| 2015 | 9.77% | 12.25% | 0.63x | 1.26x | $-1.46 Billion |
| 2016 | 8.30% | 10.90% | 0.61x | 1.25x | $-10.96 Billion |
| 2017 | 10.51% | 13.61% | 0.63x | 1.23x | $3.52 Billion |
| 2018 | 12.24% | 15.95% | 0.63x | 1.22x | $16.90 Billion |
| 2019 | 18.45% | 22.96% | 0.65x | 1.24x | $72.16 Billion |
| 2020 | 21.91% | 27.29% | 0.64x | 1.26x | $116.73 Billion |
| 2021 | 25.50% | 30.31% | 0.65x | 1.30x | $184.19 Billion |
| 2022 | 26.29% | 29.72% | 0.67x | 1.31x | $231.99 Billion |
| 2023 | 20.02% | 29.29% | 0.58x | 1.19x | $162.91 Billion |
| 2024 | 20.37% | 33.09% | 0.53x | 1.16x | $197.17 Billion |
| 2025 | 21.42% | 34.50% | 0.51x | 1.22x | $231.64 Billion |
Industry Comparison
This section compares Chugai Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $131,309,139,444
- Average return on equity (ROE) among peers: 18.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 9.59% | 0.22x | $28.30 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |